The race to stymie BTK: Zanu zings

Prashant Kapoor; Steven P. Treon

doi:10.1182/BLOOD.2020008197

The race to stymie BTK: Zanu zings

Prashant Kapoor, Steven P. Treon

Hematology

Research output: Contribution to journal › Review article › peer-review

Abstract

This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenström macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.

Original language	English (US)
Pages (from-to)	1997-1999
Number of pages	3
Journal	Blood
Volume	136
Issue number	18
DOIs	https://doi.org/10.1182/BLOOD.2020008197
State	Published - Oct 29 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD.2020008197

Fingerprint Dive into the research topics of 'The race to stymie BTK: Zanu zings'. Together they form a unique fingerprint.

Cite this

@article{7563b646ec7542258fc5c6a372f3c22f,

title = "The race to stymie BTK: Zanu zings",

abstract = "This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenstr{\"o}m macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.",

author = "Prashant Kapoor and Treon, {Steven P.}",

note = "Funding Information: Conflict-of-interest disclosure: P.K. has received research funding and has been a consultant to AbbVie, GlaxoSmithKline, Sanofi, and Takeda; has been a consultant to Cellectar, Karyopharm, and Pharmacyclics; and has received research funding from Amgen. S.P.T. has received research funding and has been a consultant to Pharmacyclics, X4 and BMS; has been a consultant to Janssen and Beigene; and has received research funding from Eli Lilly. n",

year = "2020",

month = oct,

day = "29",

doi = "10.1182/BLOOD.2020008197",

language = "English (US)",

volume = "136",

pages = "1997--1999",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "18",

}

TY - JOUR

T1 - The race to stymie BTK

T2 - Zanu zings

AU - Kapoor, Prashant

AU - Treon, Steven P.

N1 - Funding Information: Conflict-of-interest disclosure: P.K. has received research funding and has been a consultant to AbbVie, GlaxoSmithKline, Sanofi, and Takeda; has been a consultant to Cellectar, Karyopharm, and Pharmacyclics; and has received research funding from Amgen. S.P.T. has received research funding and has been a consultant to Pharmacyclics, X4 and BMS; has been a consultant to Janssen and Beigene; and has received research funding from Eli Lilly. n

PY - 2020/10/29

Y1 - 2020/10/29

N2 - This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenström macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.

AB - This issue of Blood presents a tour de force: Trotman and colleagues1 report a phase 1/2 trial of zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, and lay the groundwork for Tam et al.2 to present a head-to-head comparison of 2 BTK inhibitors, zanubrutinib and ibrutinib, in MYD88L256P mutantWaldenström macroglobulinemia (WM). These companion articles on zanubrutinibwill arguably have broad implications in WM therapeutics. The 2 trials showcase how extraordinary international collaborative efforts were instrumental in the development of zanubrutinib at warp speed for treatment of a rare B-cell malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85095396951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095396951&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020008197

DO - 10.1182/BLOOD.2020008197

M3 - Review article

C2 - 33119761

AN - SCOPUS:85095396951

VL - 136

SP - 1997

EP - 1999

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -